Impact of Colorectal Cancer Sidedness and Location on Therapy and Clinical Outcomes: Role of Blood-Based Biopsy for Personalized Treatment.
colorectal cancer
liquid biopsy
microbiota
molecular profiling
personalized treatment
sidedness
subsites
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
10 Jul 2023
10 Jul 2023
Historique:
received:
30
05
2023
revised:
05
07
2023
accepted:
06
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Colorectal cancer is one of the most common malignant diseases in the United States and worldwide, and it remains among the top three causes of cancer-related death. A new understanding of molecular characteristics has changed the profile of colorectal cancer and its treatment. Even controlling for known mutational differences, tumor side of origin has emerged as an independent prognostic factor, and one that impacts response to therapy. Left- and right-sided colon cancers differ in a number of key ways, including histology, mutational profile, carcinogenesis pathways, and microbiomes. Moreover, the frequency of certain molecular features gradually changes from the ascending colon to rectum. These, as well as features yet to be identified, are likely responsible for the ongoing role of tumor sidedness and colorectal subsites in treatment response and prognosis. Along with tumor molecular profiling, blood-based biopsy enables the identification of targetable mutations and predictive biomarkers of treatment response. With the application of known tumor characteristics including sidedness and subsites as well as the utilization of blood-based biopsy, along with the development of biomarkers and targeted therapies, the field of colorectal cancer continues to evolve towards the personalized management of a heterogeneous cancer.
Identifiants
pubmed: 37511727
pii: jpm13071114
doi: 10.3390/jpm13071114
pmc: PMC10381730
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur J Cancer. 2015 Jul;51(11):1405-14
pubmed: 25979833
Oncologist. 2016 Aug;21(8):988-94
pubmed: 27382031
Lancet Oncol. 2016 Jun;17(6):738-746
pubmed: 27108243
Clin Colorectal Cancer. 2019 Mar;18(1):e104-e116
pubmed: 30448100
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Gut. 2012 Jun;61(6):847-54
pubmed: 22427238
Dis Colon Rectum. 2018 Aug;61(8):897-902
pubmed: 29771800
Arch Med Sci. 2017 Feb 1;13(1):157-162
pubmed: 28144267
JAMA Oncol. 2017 Feb 01;3(2):211-219
pubmed: 27787550
JAMA. 2017 Jun 20;317(23):2392-2401
pubmed: 28632865
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
Biomedicines. 2020 Aug 26;8(9):
pubmed: 32858879
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
Lancet Oncol. 2014 Sep;15(10):1065-75
pubmed: 25088940
Int J Cancer. 2002 Oct 10;101(5):403-8
pubmed: 12216066
J Natl Cancer Inst. 2015 Feb 24;107(3):
pubmed: 25713148
Microorganisms. 2019 Nov 13;7(11):
pubmed: 31766208
Ann Oncol. 2018 Apr 20;29(7):1528-1534
pubmed: 29873679
Int J Colorectal Dis. 2017 Aug;32(8):1179-1190
pubmed: 28424871
Nat Med. 2019 Sep;25(9):1415-1421
pubmed: 31501609
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
Clin Colorectal Cancer. 2019 Mar;18(1):e87-e95
pubmed: 30420120
N Engl J Med. 2022 Jun 16;386(24):2261-2272
pubmed: 35657320
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18321-6
pubmed: 25489084
JAMA Surg. 2018 Jan 1;153(1):60-67
pubmed: 28975237
Br J Cancer. 2020 Mar;122(6):912-917
pubmed: 31929515
Ann Oncol. 2014 Oct;25(10):1995-2001
pubmed: 25057166
Front Oncol. 2020 Sep 15;10:568417
pubmed: 33042845
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
Dis Colon Rectum. 2015 Sep;58(9):831-7
pubmed: 26252844
Lancet Oncol. 2019 Apr;20(4):518-530
pubmed: 30857956
Ann Coloproctol. 2021 Oct;37(5):326-336
pubmed: 32972100
Ann Coloproctol. 2018 Dec;34(6):280-285
pubmed: 30630301
Cancer Med. 2018 Jul;7(7):2934-2942
pubmed: 29771009
Br J Cancer. 2018 Dec;119(12):1451-1455
pubmed: 30487637
Oncologist. 2020 May;25(5):404-413
pubmed: 31848314
Biomedicines. 2021 Mar 05;9(3):
pubmed: 33807878
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Cancers (Basel). 2019 Jul 24;11(8):
pubmed: 31344798
Oncotarget. 2017 Sep 21;8(49):86356-86368
pubmed: 29156800
Clin Cancer Res. 2018 Mar 1;24(5):1062-1072
pubmed: 29180604
J Clin Invest. 2019 Mar 11;129(4):1699-1712
pubmed: 30855275
J Gastroenterol. 2023 Mar;58(3):229-245
pubmed: 36648535
Gut. 2019 Nov;68(11):1971-1978
pubmed: 31427405
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2073-2083
pubmed: 28600626
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Gastroenterology Res. 2018 Aug;11(4):264-273
pubmed: 30116425
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancers (Basel). 2020 May 27;12(6):
pubmed: 32471160
Ann Surg Treat Res. 2019 Jun;96(6):296-304
pubmed: 31183334
Ann Oncol. 2017 Aug 01;28(8):1862-1868
pubmed: 28449055
JAMA Oncol. 2017 Feb 01;3(2):194-201
pubmed: 27722750
J Natl Cancer Inst. 2022 Jan 11;114(1):38-46
pubmed: 34467395
Cancers (Basel). 2019 Oct 16;11(10):
pubmed: 31623125
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839